Get to know our clinical trials
A trial to investigate the efficacy, safety, and tolerability of itepekimab in adult participants with chronic rhinosinusitis with nasal polyps
THE PRIMARY OBJECTIVE OF THIS STUDY IS TO INVESTIGATE THE EFFICACY AND SAFETY OF ITEPEKIMAB IN PATIENTS WITH INADEQUATELY CONTROLLED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS.
Status
In recruitment
headquarters
Pamplona
Technical Summary
- A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE III TRIAL TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ITEPEKIMAB IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED CHRONIC RHINOSINUSITIS WITH NASAL POLYPS.
- Code EudraCT: 2024-516815-26
- Protocol number: EFC18419
- Promoter: Sanofi-Aventis Recherche & Développement
- Molecule/Drug: itepekimab
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.